Nikola Tripković

Recombinant porcine factor VIII corrects thrombin generation in vitro in plasma from patients with congenital hemophilia A and inhibitors

C. Négrier, S. Meeks, G. Kenet, 2022, Research and practice in thrombosis and haemostasis.

ASPIRE Final Results Confirm Established Safety and Sustained Efficacy for Up to 4 Years of Treatment With rFVIIIFc in Previously Treated Subjects With Severe Hemophilia A

J. Oldenburg, B. Konkle, K. Pasi, 2018, Blood.